{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:22:29Z","timestamp":1762622549278,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijcha.2025.101702","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:33:15Z","timestamp":1746905595000},"page":"101702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MAGGIC risk score and drug-related adverse events of sacubitril\/valsartan: Insights from the REVIEW-HF registry"],"prefix":"10.1016","volume":"59","author":[{"given":"Daiki","family":"Akagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Shibao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshiro","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kagiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2025.101702_b0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101702_b0010","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2021","key":"10.1016\/j.ijcha.2025.101702_b0015","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ. J."},{"issue":"2021","key":"10.1016\/j.ijcha.2025.101702_b0020","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"issue":"2023","key":"10.1016\/j.ijcha.2025.101702_b0025","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"issue":"2022","key":"10.1016\/j.ijcha.2025.101702_b0030","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101702_b0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.1465","article-title":"Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035589","article-title":"Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: a retrospective cohort study","volume":"102","author":"Ko\u00e7ak","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijcha.2025.101702_b0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcha.2025.101702_b0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jjcc.2023.11.005","article-title":"Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101702_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24192","article-title":"A meta-analysis investigating the efficacy and adverse events linked to sacubitril-valsartan in various heart failure subtypes","volume":"47","author":"Ji","year":"2024","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101702_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002764","article-title":"Risk stratification by renal function and NYHA class in patients with hypotension initiated on sacubitril\/valsartan: a retrospective cohort study from 17 centres in Japan","volume":"11","author":"Kanaoka","year":"2024","journal-title":"Open Heart"},{"key":"10.1016\/j.ijcha.2025.101702_b0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101702_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40266-022-00957-8","article-title":"The prevalence of adverse drug reactions and adverse drug events from heart failure medications in frail older adults: a systematic review","volume":"39","author":"Duong","year":"2022","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijcha.2025.101702_b0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jchf.2022.11.026","article-title":"Medication-attributable adverse events in heart failure trials","volume":"11","author":"Harrington","year":"2023","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejhf.32","article-title":"Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry: validation of the MAGGIC heart failure risk score in 51 043 patients","volume":"16","author":"Sartipy","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0090","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2025.101702_b0095","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/jcpt.13699","article-title":"Effectiveness and safety of sacubitril\/valsartan for patients with hypertension and heart failure in the real-world setting: a retrospective study in China","volume":"47","author":"Zuo","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ijcha.2025.101702_b0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0105","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-24-0636","article-title":"Uptitration of sacubitril\/valsartan and outcomes in patients with heart failure - insight from the REVIEW-HF registry","author":"Doi","year":"2024","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2025.101702_b0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ehf2.12278","article-title":"Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides","volume":"5","author":"Sawano","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0115","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101702_b0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009594","article-title":"Meta-Analysis Global Group in chronic (MAGGIC) heart failure risk score: Validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction","volume":"7","author":"Rich","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2025.101702_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/jch.14969","article-title":"Sacubitril\/Valsartan for blood pressure lowering in non-dialysis-dependent chronic kidney disease Stage 3-5 patients with hypertension: a multicenter clinical study","volume":"27","author":"Yan","year":"2025","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcha.2025.101702_b0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ehf2.14166","article-title":"Influence of diabetes on sacubitril\/valsartan titration and clinical outcomes in patients hospitalized for heart failure","volume":"10","author":"Witte","year":"2023","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101702_b0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028865","article-title":"Sex differences in the effectiveness of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and sacubitril-valsartan for the treatment of heart failure","volume":"12","author":"Sohani","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2025.101702_b0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/FJC.0000000000001049","article-title":"Adverse events of sacubitril\/valsartan: a meta-analysis of randomized controlled trials: a meta-analysis of randomized controlled trials","volume":"78","author":"Huang","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcha.2025.101702_b0145","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2025.101702_b0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamacardio.2022.4427","article-title":"Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial","volume":"8","author":"Rohde","year":"2023","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcha.2025.101702_b0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014240","article-title":"Clinical implications of the New York Heart Association classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcha.2025.101702_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcha.2025.101702_b0165","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ehf2.14367","article-title":"Dose titration of sacubitril\/valsartan for heart failure with reduced ejection fraction: a real-world study","volume":"10","author":"Wang","year":"2023","journal-title":"ESC Heart Fail."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:18:13Z","timestamp":1762622293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906725001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S2352906725001058"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101702","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAGGIC risk score and drug-related adverse events of sacubitril\/valsartan: Insights from the REVIEW-HF registry","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101702"}}